Departamento de Química, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil.
Evid Based Complement Alternat Med. 2012;2012:892182. doi: 10.1155/2012/892182. Epub 2011 Aug 21.
To evaluate the effectiveness of Uncaria tomentosa in minimizing the side effects of chemotherapy and improving the antioxidant status of colorectal cancer (CRC) patients, a randomized clinical trial was conducted. Patients (43) undergoing adjuvant/palliative chemotherapy with 5-Fluorouracil/leucovorin + oxaliplatin (FOLFOX4) were split into two groups: the UT group received chemotherapy plus 300 mg of Uncaria tomentosa daily and the C group received only FOLFOX4 and served as a control. Blood samples were collected before each of the 6 cycles of chemotherapy, and hemograms, oxidative stress, enzymes antioxidants, immunologic parameters, and adverse events were analyzed. The use of 300 mg of Uncaria tomentosa daily during 6 cycles of FOLFOX4 did not change the analyzed parameters, and no toxic effects were observed.
为了评估钩藤在减轻结直肠癌（CRC）患者化疗副作用和改善抗氧化状态方面的有效性，进行了一项随机临床试验。接受 5-氟尿嘧啶/亚叶酸钙+奥沙利铂（FOLFOX4）辅助/姑息化疗的 43 名患者被分为两组：UT 组接受化疗加 300mg 钩藤每日治疗，C 组仅接受 FOLFOX4 治疗作为对照。在每 6 个化疗周期前采集血样，并分析血象、氧化应激、酶抗氧化剂、免疫参数和不良事件。在 FOLFOX4 的 6 个周期中每天使用 300mg 钩藤不会改变分析参数，并且没有观察到毒副作用。
